Healthcare News: CMS adds six new HCPCS drug codes to OPPS
Beginning July 1, coders will have six new HCPCS codes to report for specific drugs and biologicals, according to CMS Transmittal R2483CP. The new codes are:
- Q2045, injection, human fibrinogen concentrate, 1 mg
- Q2046, injection, aflibercept, 1 mg
- Q2047, injection, Peginesatide, 0.1 MG (for ESRD on Dialysis)
- Q2048, injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg
- Q2049, injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2034, influenza virus vaccine, split virus, for intramuscular use (Agriflu)
Three of the codes replace current HCPCS Level II codes. Code Q2045 will replace code J1680 (injection, human fibrinogen concentrate, 100 mg) July 1. Code Q2046 will replace C9291 (injection, aflibercept, 2 mg vial) and code Q2048 will replace J9001 (Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg).
Codes Q2045, Q2048, and Q2049 all have status indicator K (paid under OPPS; separate APC payment). Code Q2046 is assigned status indicator G (pass-through drugs and biologicals). Code Q2047 has a status indicator A (Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS). Code Q2034 falls under status indicator L (influenza vaccine; pneumococcal pneumonia vaccine).